Harrow Health Inc. (NASDAQ:HROW) is a U.S.-based ophthalmic pharmaceutical company that has steadily evolved from its roots in compounding into a leader in eye care innovation. Founded as Imprimis Pharmaceuticals, the company built its early reputation on compounding custom ophthalmic formulations for physicians and patients who needed tailored treatments. Over time, it expanded far beyond compounding, rebranding as Harrow Health to reflect its broader mission of delivering safe, accessible, and effective solutions for eye disease management. Headquartered in Nashville, Tennessee, Harrow has become one of the fastest-growing companies in the ophthalmic sector, serving eye care professionals and patients across North America.
The company’s flagship commercial arm, ImprimisRx, remains one of the leading compounding pharmacies in ophthalmology, offering a wide range of customized medications. But Harrow has strategically diversified its portfolio through acquisitions, licensing agreements, and partnerships, giving it rights to an expanding lineup of FDA-approved branded products, authorized generics, and pipeline assets. Its portfolio now addresses conditions that impact both the front and back of the eye, including dry eye disease, cataracts, glaucoma, refractive errors, and retina disorders. By combining compounding expertise with branded pharmaceuticals and generics, Harrow has created a vertically integrated business model that sets it apart from competitors.
One of the company’s most important milestones was the acquisition and commercialization of more than a dozen branded ophthalmic products, allowing Harrow to move into markets traditionally dominated by larger pharmaceutical players. This aggressive expansion strategy was accompanied by the development of new initiatives such as the VEVYE Access For All program, which proved to be a major success by driving prescription growth and demonstrating the company’s ability to improve affordability and access for patients. Building on that success, Harrow launched its Harrow Access for All (HAFA) program, a platform designed to unify access across its entire ophthalmic portfolio. By directly addressing affordability, predictability, and physician workflow integration, Harrow has effectively transformed itself from a product company into an ecosystem company.
Harrow’s vision is clear: to become the “Amazon for Ophthalmology.” By creating a seamless, centralized platform where prescribers and patients can access branded, generic, and compounded medications through HarrowAccess.com, the company is embedding itself deeply into clinical practices and patient care. This approach not only reduces administrative burdens for physicians but also builds long-term loyalty, creating high switching costs for competitors. The HAFA program, combined with Harrow’s expanding pipeline of innovative ophthalmic therapies, underscores its commitment to solving some of the biggest challenges in healthcare—access, affordability, and patient adherence.
Today, Harrow Health stands at the forefront of ophthalmic disease management, offering one of the most comprehensive portfolios in the industry. Its growth trajectory reflects both its entrepreneurial beginnings in compounding and its transformation into a fully integrated pharmaceutical company. With a proven track record of strategic acquisitions, a growing suite of innovative products, and bold initiatives that redefine patient access, Harrow has positioned itself as a dominant force in eye care. The company’s commitment to affordability and innovation continues to set it apart, making it a rising leader in one of the most critical areas of healthcare.
Harrow Expands Innovative Access Model With HAFA
Harrow Health has once again demonstrated why it is one of the most forward-thinking companies in ophthalmology with the launch of the Harrow Access for All program, known as HAFA. Building on the success of the VEVYE Access for All initiative, which drove a 66% prescription growth in just the second quarter of 2025, HAFA represents a bold expansion of this proven model across Harrow’s entire ophthalmic portfolio. This is not just a marketing move—it is a structural shift in how patients, physicians, and pharmacies interact in the eye care industry, one that could drive significant long-term growth in prescriptions, patient loyalty, and ultimately revenue.
The brilliance of HAFA lies in its phased rollout strategy. Rather than attempting to transform the entire portfolio overnight, Harrow is rolling out the program in three carefully planned phases. Phase one begins in Q4 2025 with its specialty products, including the much-anticipated launch of BYQLOVI. Phase two follows in 2026 with the addition of authorized generics, and by 2027, phase three will see HAFA encompass Harrow’s full product range of specialty, generics, and compounded ophthalmic medications. This measured approach allows Harrow to capture early wins, demonstrate proof of concept across multiple drug classes, and gradually scale up without overextending operational capacity.
CHECK THIS OUT: Saudi Arabia Wants CEL-SCI (CVM)’s Multikine Now! and Aligos Therapeutics (ALGS) Doubles Cash to $122.9M.
Addressing the Cost Barrier in Ophthalmology
One of the most persistent problems in healthcare, particularly in specialty pharmaceuticals, is the cost barrier that prevents patients from filling or refilling prescriptions. HAFA directly tackles this challenge with a simple and transparent pricing model. Out-of-pocket costs are capped at $59, while many commercially insured patients could pay as little as $0. This predictable pricing structure provides patients with peace of mind, reduces the financial burden of sight-preserving medications, and increases the likelihood of long-term adherence.
The economic logic of HAFA is compelling. By trading some margin for volume, Harrow positions itself to capture more consistent recurring prescriptions. In pharmaceuticals, adherence is often the true driver of revenue, and by removing cost as a barrier, Harrow ensures its medications are filled, refilled, and consistently used. Over time, the volume generated by HAFA could dramatically outpace any margin concessions, creating stronger economics for both the company and its physician partners.
HarrowAccess.com: Building a Digital Moat
The HAFA initiative is more than just pricing—it is powered by technology through the HarrowAccess.com portal. This centralized platform enables prescribers to create customized decision trees for their practice, ensuring patients receive the right Harrow medication based on coverage, affordability, and clinical need. By embedding itself into the daily workflow of ophthalmologists and optometrists, Harrow creates a powerful loyalty mechanism. Switching to a competitor’s product would no longer just mean writing a different prescription; it would mean disrupting an entire prescribing system already optimized for efficiency.
The portal also helps reduce the considerable administrative burden that doctors face, particularly around prior authorizations, refill tracking, and insurance management. For time-constrained practitioners, Harrow’s products become the path of least resistance, creating a structural competitive advantage. This integration of access, affordability, and technology positions Harrow not just as a pharmaceutical company but as a platform that redefines the ophthalmic prescribing experience.
From Product Company to Ecosystem Leader
Perhaps the most strategically significant aspect of HAFA is Harrow’s vision of becoming the “Amazon for Ophthalmology.” By unifying branded drugs, authorized generics, and compounded medications under one affordable and accessible system, Harrow is transforming itself from a product-driven company into an ecosystem-driven company. This shift creates network effects: as more physicians and patients engage with HAFA, the platform becomes stickier, and the cost of switching to competitors rises.
Harrow is no longer simply selling drugs—it is offering a comprehensive ecosystem of ophthalmic disease management solutions. This positions the company to capture larger market share across multiple therapeutic areas, including dry eye disease, wet AMD, cataracts, glaucoma, and retina diseases. Over time, Harrow’s platform strategy could give it dominance in ophthalmology similar to what companies like McKesson or Cardinal have achieved in broader pharmaceutical distribution, but with a specialty focus that delivers higher margins and deeper integration with prescribers.
Investor Implications: Why HAFA is a Bullish Catalyst
For investors, the HAFA initiative signals several bullish implications. First, it shows management’s ability to take a successful pilot program and scale it into a company-wide growth driver. Second, it positions Harrow for sustainable revenue growth by increasing prescription volumes, refill rates, and physician loyalty. Third, it creates durable competitive advantages through technological integration and patient-first pricing strategies that are difficult for rivals to replicate.
Most importantly, HAFA strengthens Harrow’s long-term investment case by combining financial discipline with strategic innovation. By reducing barriers to access, embedding its products into clinical workflows, and building a scalable digital platform, Harrow has created a growth engine that aligns with both patient needs and physician incentives. In a healthcare environment increasingly focused on affordability and efficiency, Harrow is ahead of the curve.
Conclusion: Harrow’s Platform Strategy Unlocks New Growth
The launch of the HAFA program is a transformative milestone for Harrow Health. By expanding its successful affordability and access model across the entire ophthalmic portfolio, the company is ensuring that patients have consistent, predictable access to critical medications, while simultaneously strengthening physician loyalty and creating long-term revenue visibility. The integration of the HarrowAccess.com portal, combined with the phased rollout strategy, positions the company to capture incremental gains and scale into a dominant ecosystem player in ophthalmology.
For investors, HAFA underscores why Harrow remains one of the most compelling growth stories in specialty pharmaceuticals. With its vision of becoming the “Amazon for Ophthalmology,” Harrow is not just selling products—it is reshaping the future of eye care.
READ ALSO: Exact Sciences (EXAS) Just Made Cancer Detection 100x Easier! and Soleno Therapeutics (SLNO): The Biotech Company That Could Make You Rich.
